J&J: to present its advances in hematology

(CercleFinance.com) - Johnson & Johnson will present more than 90 abstracts covering data from its portfolio and sib pipeline in the treatment of blood cancers at the 66th annual meeting of the American Society of Hematology (ASH) in San Diego, December 7-10.


These data highlight innovative therapies for multiple myeloma and myeloid and B-cell diseases, as well as research into rare diseases such as warm autoimmune hemolytic anemia (wAIHA) and neonatal alloimmune thrombocytopenia (FNAIT).

The program includes phase 2 and 3 results for treatments such as DARZALEX FASPRO, TECVAYLI, CARVYKTI, and TALVEY, with a focus on combination regimens and options for patients not eligible for transplantation.


Copyright (c) 2024 CercleFinance.com. All rights reserved.